Compare AANJANEYA LIFECARE with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS CADILA HEALTHCARE DR. DATSONS LABS/
CADILA HEALTHCARE
 
P/E (TTM) x -10.9 14.4 - View Chart
P/BV x 0.2 2.8 5.8% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 DR. DATSONS LABS   CADILA HEALTHCARE
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
CADILA HEALTHCARE
Mar-18
DR. DATSONS LABS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs126558 22.5%   
Low Rs31362 8.5%   
Sales per share (Unadj.) Rs133.0116.3 114.4%  
Earnings per share (Unadj.) Rs0.217.9 0.8%  
Cash flow per share (Unadj.) Rs6.623.1 28.6%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs128.885.4 150.8%  
Shares outstanding (eoy) m31.661,023.74 3.1%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.64.0 14.9%   
Avg P/E ratio x516.125.7 2,005.9%  
P/CF ratio (eoy) x11.819.9 59.6%  
Price / Book Value ratio x0.65.4 11.3%  
Dividend payout %019.6 0.0%   
Avg Mkt Cap Rs m2,477470,664 0.5%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m5618,545 0.3%   
Avg. sales/employee Rs ThNM10,072.7-  
Avg. wages/employee Rs ThNM1,569.1-  
Avg. net profit/employee Rs ThNM1,547.7-  
INCOME DATA
Net Sales Rs m4,211119,049 3.5%  
Other income Rs m791,132 7.0%   
Total revenues Rs m4,289120,181 3.6%   
Gross profit Rs m56928,475 2.0%  
Depreciation Rs m2045,388 3.8%   
Interest Rs m430911 47.2%   
Profit before tax Rs m1323,308 0.1%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m65,644 0.1%   
Profit after tax Rs m518,292 0.0%  
Gross profit margin %13.523.9 56.5%  
Effective tax rate %48.024.2 198.4%   
Net profit margin %0.115.4 0.7%  
BALANCE SHEET DATA
Current assets Rs m6,85282,005 8.4%   
Current liabilities Rs m6,71160,720 11.1%   
Net working cap to sales %3.317.9 18.7%  
Current ratio x1.01.4 75.6%  
Inventory Days Days16173 219.9%  
Debtors Days Days31898 324.0%  
Net fixed assets Rs m3,67383,703 4.4%   
Share capital Rs m3171,024 30.9%   
"Free" reserves Rs m3,76186,421 4.4%   
Net worth Rs m4,07887,445 4.7%   
Long term debt Rs m1,67125,551 6.5%   
Total assets Rs m12,633180,653 7.0%  
Interest coverage x1.026.6 3.9%   
Debt to equity ratio x0.40.3 140.2%  
Sales to assets ratio x0.30.7 50.6%   
Return on assets %3.410.6 32.4%  
Return on equity %0.120.9 0.6%  
Return on capital %7.722.0 34.9%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96442,683 2.3%   
Fx outflow Rs m60711,242 5.4%   
Net fx Rs m35731,441 1.1%   
CASH FLOW
From Operations Rs m1,3459,193 14.6%  
From Investments Rs m-2,256-9,737 23.2%  
From Financial Activity Rs m-1,200515 -233.0%  
Net Cashflow Rs m-2,111-29 7,278.3%  

Share Holding

Indian Promoters % 4.5 74.8 6.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.3 -  
FIIs % 1.4 5.9 22.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 11.0 855.5%  
Shareholders   20,807 44,069 47.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  TTK HEALTHCARE  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare DR. DATSONS LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 5-YR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS